171 related articles for article (PubMed ID: 21879387)
1. Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy.
Kang SH; Cho HJ; Shim G; Lee S; Kim SH; Choi HG; Kim CW; Oh YK
Pharm Res; 2011 Dec; 28(12):3069-78. PubMed ID: 21879387
[TBL] [Abstract][Full Text] [Related]
2. Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug.
Shim G; Han SE; Yu YH; Lee S; Lee HY; Kim K; Kwon IC; Park TG; Kim YB; Choi YS; Kim CW; Oh YK
J Control Release; 2011 Oct; 155(1):60-6. PubMed ID: 20971142
[TBL] [Abstract][Full Text] [Related]
3. Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA.
Yu YH; Kim E; Park DE; Shim G; Lee S; Kim YB; Kim CW; Oh YK
Eur J Pharm Biopharm; 2012 Feb; 80(2):268-73. PubMed ID: 22108492
[TBL] [Abstract][Full Text] [Related]
4. Enhanced transfection rates of small-interfering RNA using dioleylglutamide-based magnetic lipoplexes.
Lee S; Shim G; Kim S; Kim YB; Kim CW; Byun Y; Oh YK
Nucleic Acid Ther; 2011 Jun; 21(3):165-72. PubMed ID: 21749293
[TBL] [Abstract][Full Text] [Related]
5. Enhanced intrapulmonary delivery of anticancer siRNA for lung cancer therapy using cationic ethylphosphocholine-based nanolipoplexes.
Shim G; Choi HW; Lee S; Choi J; Yu YH; Park DE; Choi Y; Kim CW; Oh YK
Mol Ther; 2013 Apr; 21(4):816-24. PubMed ID: 23380818
[TBL] [Abstract][Full Text] [Related]
6. RGD peptide conjugation results in enhanced antitumor activity of PD0325901 against glioblastoma by both tumor-targeting delivery and combination therapy.
Hou J; Diao Y; Li W; Yang Z; Zhang L; Chen Z; Wu Y
Int J Pharm; 2016 May; 505(1-2):329-40. PubMed ID: 27085642
[TBL] [Abstract][Full Text] [Related]
7. Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes.
Sonoke S; Ueda T; Fujiwara K; Sato Y; Takagaki K; Hirabayashi K; Ohgi T; Yano J
Cancer Res; 2008 Nov; 68(21):8843-51. PubMed ID: 18974128
[TBL] [Abstract][Full Text] [Related]
8. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
Lyubynska N; Gorman MF; Lauchle JO; Hong WX; Akutagawa JK; Shannon K; Braun BS
Sci Transl Med; 2011 Mar; 3(76):76ra27. PubMed ID: 21451123
[TBL] [Abstract][Full Text] [Related]
9. A Combination of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and MEK (MAP Kinase/ERK Kinase) Inhibitor PD0325901 Increases Bone Formation in a Murine Model of Neurofibromatosis Type I Pseudarthrosis.
El-Hoss J; Cheng T; Carpenter EC; Sullivan K; Deo N; Mikulec K; Little DG; Schindeler A
J Bone Joint Surg Am; 2014 Jul; 96(14):e117. PubMed ID: 25031379
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
[TBL] [Abstract][Full Text] [Related]
11. Targeting MEK is effective chemoprevention of hepatocellular carcinoma in TGF-alpha-transgenic mice.
Wentz SC; Wu H; Yip-Schneider MT; Hennig M; Klein PJ; Sebolt-Leopold J; Schmidt CM
J Gastrointest Surg; 2008 Jan; 12(1):30-7. PubMed ID: 17987349
[TBL] [Abstract][Full Text] [Related]
12. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
Burmi RS; Maginn EN; Gabra H; Stronach EA; Wasan HS
Cancer Biol Ther; 2019; 20(1):21-30. PubMed ID: 30261145
[TBL] [Abstract][Full Text] [Related]
13. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M
Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351
[TBL] [Abstract][Full Text] [Related]
14. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing.
Cardoso AL; Simões S; de Almeida LP; Pelisek J; Culmsee C; Wagner E; Pedroso de Lima MC
J Gene Med; 2007 Mar; 9(3):170-83. PubMed ID: 17351968
[TBL] [Abstract][Full Text] [Related]
15. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.
Ciuffreda L; Del Bufalo D; Desideri M; Di Sanza C; Stoppacciaro A; Ricciardi MR; Chiaretti S; Tavolaro S; Benassi B; Bellacosa A; Foà R; Tafuri A; Cognetti F; Anichini A; Zupi G; Milella M
Neoplasia; 2009 Aug; 11(8):720-31. PubMed ID: 19649202
[TBL] [Abstract][Full Text] [Related]
16. Anionic amino acid-derived cationic lipid for siRNA delivery.
Suh MS; Shim G; Lee HY; Han SE; Yu YH; Choi Y; Kim K; Kwon IC; Weon KY; Kim YB; Oh YK
J Control Release; 2009 Dec; 140(3):268-76. PubMed ID: 19567256
[TBL] [Abstract][Full Text] [Related]
17. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.
Henderson YC; Chen Y; Frederick MJ; Lai SY; Clayman GL
Mol Cancer Ther; 2010 Jul; 9(7):1968-76. PubMed ID: 20587665
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy.
Duan X; Mu M; Yan J; Bai L; Zhong L; Zhu Y; Pan H; Zhang M; Shi J
Int J Nanomedicine; 2018; 13():1443-1456. PubMed ID: 29563798
[TBL] [Abstract][Full Text] [Related]
19. Effective Skin Cancer Treatment by Topical Co-delivery of Curcumin and STAT3 siRNA Using Cationic Liposomes.
Jose A; Labala S; Ninave KM; Gade SK; Venuganti VVK
AAPS PharmSciTech; 2018 Jan; 19(1):166-175. PubMed ID: 28639178
[TBL] [Abstract][Full Text] [Related]
20. Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways.
Liu D; Xing M
Thyroid; 2008 Aug; 18(8):853-64. PubMed ID: 18651802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
